Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE-lung: amivantamab + bevacizumab with continued osimertinib or lazertinib in EGFR-mutant advanced NSCLC after progression
NL-OMON59186Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amivantamab, bevacizumab, osimertinib and lazertinib in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Objective response rate. Started Jul 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on NL-OMON59186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59186.